...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neuroscience Methods >Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures.
【24h】

Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures.

机译：基于微阵列的mRNA谱分析技术用于鉴定精神疾病和药物特征的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The gene expression profiles of human postmortem parietal and prefrontal cortex samples of normal controls and patients with bipolar disease, or human neuroblastoma flat (NBFL) cells treated with the mood-stabilizing drug, valproate, were used to compare the performance of Affymetrix oligonucleotide U133A GeneChips and Agilent Human 1 cDNA microarrays. Among those genes represented on both platforms, the oligo array identified 26-53% more differentially expressed genes compared to the cDNA array in the three experiments, when identical fold change and t-test criteria were applied. The increased sensitivity was primarily the result of more robust fold changes measured by the oligonucleotide system. Essentially all gene changes overlapping between the two platforms were co-directional, and ranged from 4 to 19% depending upon the amount of biological variability within and between the comparison groups. Q-PCR validation rates were virtually identical for the two platforms, with 23-24% validation in the prefrontal cortex experiment, and 56% for both platforms in the cell culture experiment. Validated genes included dopa decarboxylase, dopamine beta-hydroxylase, and dihydropyrimidinase-related protein 3, which were decreased in NBFL cells exposed to valproate, and spinocerebellar ataxia 7, which was increased in bipolar disease. The modest overlap but similar validation rates show that each microarray system identifies a unique set of differentially expressed genes, and thus the greatest information is obtained from the use of both platforms.
机译：使用正常对照和躁郁症患者的人死后顶叶和额叶皮层样本的基因表达谱，或用情绪稳定药物丙戊酸治疗的人神经母细胞瘤扁平（NBFL）细胞，比较Affymetrix寡核苷酸U133A GeneChips的性能和Agilent Human 1 cDNA微阵列。在三个实验中，当使用相同的倍数变化和t-检验标准时，在两个平台上代表的那些基因中，寡核苷酸阵列比cDNA阵列鉴定出差异表达的基因多26-53％。灵敏度的提高主要是寡核苷酸系统测得的更可靠的倍数变化的结果。基本上，两个平台之间重叠的所有基因变化都是同向的，取决于比较组内和比较组之间的生物变异量，其范围为4％至19％。两种平台的Q-PCR验证率几乎相同，前额叶皮层实验的验证率为23-24％，细胞培养实验的两种平台的验证率为56％。验证的基因包括多巴脱羧酶，多巴胺β-羟化酶和二氢嘧啶酶相关蛋白3（在暴露于丙戊酸盐的NBFL细胞中减少）和脊髓小脑共济失调7（在双相性疾病中增加）。适度的重叠但相似的验证率表明，每个微阵列系统都可以识别一组独特的差异表达基因，因此可以从两个平台的使用中获得最大的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号